ZA200506580B - Use of palonsetron treating post-operative nausea and vomiting - Google Patents
Use of palonsetron treating post-operative nausea and vomiting Download PDFInfo
- Publication number
- ZA200506580B ZA200506580B ZA200506580A ZA200506580A ZA200506580B ZA 200506580 B ZA200506580 B ZA 200506580B ZA 200506580 A ZA200506580 A ZA 200506580A ZA 200506580 A ZA200506580 A ZA 200506580A ZA 200506580 B ZA200506580 B ZA 200506580B
- Authority
- ZA
- South Africa
- Prior art keywords
- medicament dose
- vomiting
- palonosetron
- dose
- treatment
- Prior art date
Links
- 208000031649 Postoperative Nausea and Vomiting Diseases 0.000 title claims abstract description 53
- 206010047700 Vomiting Diseases 0.000 claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 15
- 229960002131 palonosetron Drugs 0.000 claims abstract description 11
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims description 43
- 238000011282 treatment Methods 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 18
- 230000002265 prevention Effects 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 230000008673 vomiting Effects 0.000 claims description 6
- 238000002512 chemotherapy Methods 0.000 claims description 4
- 206010066962 Procedural nausea Diseases 0.000 claims description 3
- OLDRWYVIKMSFFB-SSPJITILSA-N palonosetron hydrochloride Chemical compound Cl.C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 OLDRWYVIKMSFFB-SSPJITILSA-N 0.000 claims 20
- 229960003359 palonosetron hydrochloride Drugs 0.000 claims 20
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 13
- 229930195725 Mannitol Natural products 0.000 claims 13
- 239000000594 mannitol Substances 0.000 claims 13
- 235000010355 mannitol Nutrition 0.000 claims 13
- 239000000126 substance Substances 0.000 claims 13
- 238000004519 manufacturing process Methods 0.000 claims 8
- 239000001509 sodium citrate Substances 0.000 claims 8
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims 8
- 235000019263 trisodium citrate Nutrition 0.000 claims 8
- 229940038773 trisodium citrate Drugs 0.000 claims 8
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 5
- 238000001959 radiotherapy Methods 0.000 claims 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 229940100688 oral solution Drugs 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940127558 rescue medication Drugs 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 229960001855 mannitol Drugs 0.000 claims 1
- 102000035037 5-HT3 receptors Human genes 0.000 abstract description 5
- 108091005477 5-HT3 receptors Proteins 0.000 abstract description 5
- 239000002464 receptor antagonist Substances 0.000 abstract description 5
- 229940044551 receptor antagonist Drugs 0.000 abstract description 5
- 239000002895 emetic Substances 0.000 abstract description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 14
- 238000001356 surgical procedure Methods 0.000 description 11
- MFWNKCLOYSRHCJ-AGUYFDCRSA-N 1-methyl-N-[(1S,5R)-9-methyl-9-azabicyclo[3.3.1]nonan-3-yl]-3-indazolecarboxamide Chemical compound C1=CC=C2C(C(=O)NC3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-AGUYFDCRSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 5
- 239000002111 antiemetic agent Substances 0.000 description 5
- 229960005343 ondansetron Drugs 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- FELGMEQIXOGIFQ-UHFFFAOYSA-N Ondansetron Chemical compound CC1=NC=CN1CC1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-UHFFFAOYSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 230000003474 anti-emetic effect Effects 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 4
- -1 sc opolamine) Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 229940072018 zofran Drugs 0.000 description 4
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 3
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 206010041349 Somnolence Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229960003413 dolasetron Drugs 0.000 description 3
- 229960003727 granisetron Drugs 0.000 description 3
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 206010010774 Constipation Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229940125683 antiemetic agent Drugs 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- 108091008690 chemoreceptors Proteins 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000002695 general anesthesia Methods 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 229940127240 opiate Drugs 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- GLWVPEGTRWJXSQ-UHFFFAOYSA-N 2-hydroxy-8-azatricyclo[5.3.1.03,8]undeca-2,4,6-trien-10-one Chemical class OC=1C2C(CN3C(=CC=CC=13)C2)=O GLWVPEGTRWJXSQ-UHFFFAOYSA-N 0.000 description 1
- KLUNAVKHVFZQKF-UHFFFAOYSA-N 3-(imidazol-1-ylmethyl)-1,2,3,9-tetrahydrocarbazol-4-one Chemical class C1CC=2NC3=CC=CC=C3C=2C(=O)C1CN1C=CN=C1 KLUNAVKHVFZQKF-UHFFFAOYSA-N 0.000 description 1
- 241000180579 Arca Species 0.000 description 1
- 229930091051 Arenine Natural products 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 101100275990 Drosophila melanogaster Naus gene Proteins 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- SNIXRMIHFOIVBB-UHFFFAOYSA-N N-Hydroxyl-tryptamine Chemical compound C1=CC=C2C(CCNO)=CNC2=C1 SNIXRMIHFOIVBB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010052211 Oesophageal rupture Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 210000003818 area postrema Anatomy 0.000 description 1
- 229940054066 benzamide antipsychotics Drugs 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- FFSAXUULYPJSKH-UHFFFAOYSA-N butyrophenone Chemical class CCCC(=O)C1=CC=CC=C1 FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- RMEDXOLNCUSCGS-UHFFFAOYSA-N droperidol Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CC=C(N2C(NC3=CC=CC=C32)=O)CC1 RMEDXOLNCUSCGS-UHFFFAOYSA-N 0.000 description 1
- 229960000394 droperidol Drugs 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000002322 enterochromaffin cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960003607 granisetron hydrochloride Drugs 0.000 description 1
- QYZRTBKYBJRGJB-UHFFFAOYSA-N hydron;1-methyl-n-(9-methyl-9-azabicyclo[3.3.1]nonan-3-yl)indazole-3-carboxamide;chloride Chemical compound Cl.C1=CC=C2C(C(=O)NC3CC4CCCC(C3)N4C)=NN(C)C2=C1 QYZRTBKYBJRGJB-UHFFFAOYSA-N 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical class N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- BWHLPLXXIDYSNW-UHFFFAOYSA-N ketorolac tromethamine Chemical compound OCC(N)(CO)CO.OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 BWHLPLXXIDYSNW-UHFFFAOYSA-N 0.000 description 1
- TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical compound CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 description 1
- 229960004503 metoclopramide Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- MVKDKUUCCOPJSG-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)benzamide Chemical class C1N(CC2)CCC2C1NC(=O)C1=CC=CC=C1 MVKDKUUCCOPJSG-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 150000002990 phenothiazines Chemical class 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229960003910 promethazine Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960003688 tropisetron Drugs 0.000 description 1
- UIVFDCIXTSJXBB-ITGUQSILSA-N tropisetron Chemical compound C1=CC=C[C]2C(C(=O)O[C@H]3C[C@H]4CC[C@@H](C3)N4C)=CN=C21 UIVFDCIXTSJXBB-ITGUQSILSA-N 0.000 description 1
- 230000001515 vagal effect Effects 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 229950004681 zacopride Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US44834203P | 2003-02-18 | 2003-02-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200506580B true ZA200506580B (en) | 2006-06-28 |
Family
ID=32908576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200506580A ZA200506580B (en) | 2003-02-18 | 2005-08-17 | Use of palonsetron treating post-operative nausea and vomiting |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20060074101A1 (da) |
| EP (2) | EP1596862B1 (da) |
| JP (1) | JP2006517944A (da) |
| KR (1) | KR101113087B1 (da) |
| CN (1) | CN1750822A (da) |
| AT (1) | ATE490774T1 (da) |
| AU (1) | AU2004212704B2 (da) |
| BR (1) | BRPI0407549A (da) |
| CA (1) | CA2515946C (da) |
| CU (1) | CU23587B7 (da) |
| CY (1) | CY1111312T1 (da) |
| DE (1) | DE602004030424D1 (da) |
| DK (1) | DK1596862T3 (da) |
| EA (1) | EA013836B1 (da) |
| EC (1) | ECSP055970A (da) |
| ES (1) | ES2357769T3 (da) |
| GE (1) | GEP20104908B (da) |
| HK (1) | HK1076402A1 (da) |
| HR (1) | HRP20050709A2 (da) |
| IS (1) | IS7983A (da) |
| MX (1) | MXPA05008757A (da) |
| MY (1) | MY143789A (da) |
| NO (1) | NO20054296L (da) |
| NZ (1) | NZ541862A (da) |
| PL (1) | PL378122A1 (da) |
| PT (1) | PT1596862E (da) |
| SI (1) | SI1596862T1 (da) |
| TW (1) | TWI355936B (da) |
| UA (1) | UA96254C2 (da) |
| UY (1) | UY28193A1 (da) |
| WO (1) | WO2004073714A1 (da) |
| ZA (1) | ZA200506580B (da) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL155447A0 (en) | 2000-10-20 | 2003-11-23 | Eisai Co Ltd | Nitrogenous aromatic ring compounds |
| AU2003302072A1 (en) * | 2002-11-15 | 2004-06-15 | Helsinn Healthcare Sa | Palonosetron for the treatment of chemotherapy-induced emesis |
| JO2735B1 (en) | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formations of balloonosterone |
| US8598219B2 (en) | 2003-01-30 | 2013-12-03 | Helsinn Healthcare Sa | Liquid pharmaceutical formulations of palonosetron |
| US20070196491A1 (en) * | 2006-01-27 | 2007-08-23 | Eurand, Inc. | Drug delivery systems comprising weakly basic drugs and organic acids |
| ES2550035T3 (es) * | 2006-01-27 | 2015-11-04 | Adare Pharmaceuticals, Inc. | Sistemas de administración de fármacos que comprenden un agente de bloqueo selectivo de la serotonina 5-HT3 débilmente básico y ácidos orgánicos |
| WO2008049552A1 (en) * | 2006-10-24 | 2008-05-02 | Helsinn Healthcare S.A. | Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability |
| TWI429436B (zh) * | 2007-04-10 | 2014-03-11 | Helsinn Therapeutics Us Inc | 使用生長激素促泌素治療或預防嘔吐之方法 |
| US20090155363A1 (en) * | 2007-12-14 | 2009-06-18 | Todd Maibach | Methods for oral administration of active drugs |
| EP2286814B1 (en) | 2008-05-15 | 2013-10-16 | Hisamitsu Pharmaceutical Co., Inc. | Transdermal preparation containing palonosetron |
| US20100143461A1 (en) * | 2008-12-08 | 2010-06-10 | Ben-Zion Solomon | Palonosetron formulation |
| KR101779991B1 (ko) | 2009-05-20 | 2017-09-19 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 병소성 전정 질환을 치료하기 위한 세로토닌 5-ｈｔ3 수용체 길항제의 용도 |
| ES2432618T3 (es) * | 2009-05-20 | 2013-12-04 | Inserm (Institut National De La Santé Et De La Recherche Medicale) | Antagonistas del receptor 5-HT3 de serotonina para usar en el tratamiento o prevención de una patología del oído interno con déficit vestibular |
| US20110003005A1 (en) * | 2009-07-06 | 2011-01-06 | Gopi Venkatesh | Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions |
| US20120253046A1 (en) | 2009-11-13 | 2012-10-04 | Helsinn Healthcare S.A. | Palonosetron metabolites |
| EP2722045B1 (en) | 2009-11-18 | 2016-07-06 | Helsinn Healthcare SA | Compositions for treating centrally mediated nausea and vomiting |
| MY159393A (en) * | 2009-11-18 | 2016-12-30 | Helsinn Healthcare Sa | Compositions for treating centrally mediated nausea and vomiting |
| KR101368587B1 (ko) * | 2010-12-27 | 2014-03-05 | 주식회사 삼양바이오팜 | 오심 또는 구토 방지용 조성물 |
| WO2014004126A1 (en) | 2012-06-26 | 2014-01-03 | Fleming C Andrew | Treating postoperative nausea and vomiting |
| WO2015099381A1 (ko) | 2013-12-23 | 2015-07-02 | 주식회사 삼양바이오팜 | 팔로노세트론을 함유하는 약학 조성물 |
| JP7158723B2 (ja) | 2016-04-14 | 2022-10-24 | センソリオン | 耳疾患の処置における使用のための（＋）－アザセトロン |
| JP6768404B2 (ja) * | 2016-08-12 | 2020-10-14 | 武田テバファーマ株式会社 | パロノセトロン又はその薬学的に許容される塩を含む医薬組成物 |
| JP6705348B2 (ja) * | 2016-09-23 | 2020-06-03 | ニプロ株式会社 | 液体製剤、及び、パロノセトロンの安定性を向上する方法 |
| GB201618425D0 (en) * | 2016-11-01 | 2016-12-14 | Acacia Pharma Ltd | method |
| KR101802183B1 (ko) * | 2016-11-16 | 2017-11-28 | 주식회사 유영제약 | 팔로노세트론을 활성성분으로 함유하는 약제학적 조성물 |
| ES2943933T3 (es) * | 2018-01-12 | 2023-06-16 | Orion Corp | Colirios de palonosetrón para el tratamiento o la prevención de náuseas y vómitos |
| CN108703960A (zh) * | 2018-07-25 | 2018-10-26 | 无锡鑫连鑫生物医药科技有限公司 | 一种帕洛诺司琼缓释微球及其制备方法和使用方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4695578A (en) | 1984-01-25 | 1987-09-22 | Glaxo Group Limited | 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances |
| DE3687080T2 (de) | 1985-04-27 | 1993-03-25 | Beecham Group Plc | Azabicyclononyl-indazol-carboxamid mit 5-ht-antagonistischer wirkung. |
| US4937247A (en) | 1985-04-27 | 1990-06-26 | Beecham Group P.L.C. | 1-acyl indazoles |
| US5578628A (en) | 1985-06-25 | 1996-11-26 | Glaxo Group Limited | Medicaments for the treatment of nausea and vomiting |
| US5240954A (en) | 1985-06-25 | 1993-08-31 | Glaxo Group Limited | Medicaments |
| GB8516083D0 (en) | 1985-06-25 | 1985-07-31 | Glaxo Group Ltd | Heterocyclic compounds |
| US4906755A (en) | 1986-11-03 | 1990-03-06 | Merrell Dow Pharmaceuticals Inc. | Esters of hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3-(4H)-one and related compounds |
| US4707484A (en) | 1986-11-25 | 1987-11-17 | Hoffmann-La Roche Inc. | Substituted piperidinomethylindolone and cyclopent(b)indolone derivatives |
| US5011846A (en) | 1988-02-23 | 1991-04-30 | Merrell Dow Pharmaceuticals Inc. | Medicament compositions derived from quinolizine and quinolizinone and methods of use thereof |
| US5344658A (en) * | 1989-06-28 | 1994-09-06 | Glaxo Group Limited | Process and composition using ondansetron |
| GB8914804D0 (en) * | 1989-06-28 | 1989-08-16 | Glaxo Group Ltd | Process |
| EP0430190B1 (en) * | 1989-11-28 | 1995-07-05 | Syntex (U.S.A.) Inc. | New tricyclic compounds |
| US5189041A (en) | 1990-11-16 | 1993-02-23 | Syntex (U.S.A.) Inc. | Tricyclic 5-ht3 receptor antagonists |
| US5137893A (en) | 1991-03-07 | 1992-08-11 | G. D. Searle & Co. | Pharmaceutically useful meso-azacyclic amides of imidazopyridine carboxylic acids and analogs thereof |
| US5491148A (en) | 1991-04-26 | 1996-02-13 | Syntex (U.S.A.) Inc. | Isoquinolinone and dihydroisoquinolinone 5-HT3 receptor antagonists |
| US5272137A (en) * | 1992-02-14 | 1993-12-21 | Mcneil-Pfc, Inc. | Aqueous pharmaceutical suspension for pharmaceutical actives |
| GB9305593D0 (en) | 1993-03-18 | 1993-05-05 | Smithkline Beecham Plc | Pharmaceuticals |
| US5492914A (en) | 1994-07-28 | 1996-02-20 | Syntex (U.S.A.) Inc. | 2-(1-azabicyclo[2.2.2]oct-3 s-yl)-6-hydroxy-2,4,5,6-tetrahydro-1H-benz[DE]is[2.2.2]oct-3's-yl)-6-hydroxy-2,3,3a,4,5,6-hexahydro-1h-benz [DE]isoquinolin-1-one and individual stereoisomers thereof |
| GB9423588D0 (en) * | 1994-11-22 | 1995-01-11 | Glaxo Wellcome Inc | Compositions |
| GB9423511D0 (en) | 1994-11-22 | 1995-01-11 | Glaxo Wellcome Inc | Compositions |
| GB9625589D0 (en) * | 1996-12-10 | 1997-01-29 | Boots Co Plc | Therapeutic agents |
| US20030095926A1 (en) * | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract |
| US6294548B1 (en) | 1998-05-04 | 2001-09-25 | Hoffmann-La Roche Inc. | Multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H-indazole-3-carboxamide hydrochloride |
| CA2321191A1 (en) * | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Multivalent agonists, partial agonists, inverse agonists and antagonists of the 5-ht3 receptors |
| DK1124535T3 (da) * | 1998-10-27 | 2003-01-06 | Alcon Lab Inc | Konserverende system til topisk indgivelige farmaceutiske præparater indeholdende en fedtsyre/aminosyresæbe |
| US6196963B1 (en) * | 1999-03-02 | 2001-03-06 | Medtronic Ave, Inc. | Brachytherapy device assembly and method of use |
| AU2003237657A1 (en) * | 2002-05-24 | 2003-12-12 | Epidauros Biotechnologie Ag | Means and methods for improved treatment using "setrones" |
| AU2003302072A1 (en) * | 2002-11-15 | 2004-06-15 | Helsinn Healthcare Sa | Palonosetron for the treatment of chemotherapy-induced emesis |
| JO2735B1 (en) * | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formations of balloonosterone |
| US8598219B2 (en) * | 2003-01-30 | 2013-12-03 | Helsinn Healthcare Sa | Liquid pharmaceutical formulations of palonosetron |
-
2004
- 2004-02-17 MY MYPI20040515A patent/MY143789A/en unknown
- 2004-02-17 TW TW093103716A patent/TWI355936B/zh not_active IP Right Cessation
- 2004-02-18 WO PCT/EP2004/001558 patent/WO2004073714A1/en active Application Filing
- 2004-02-18 GE GEAP20048984A patent/GEP20104908B/en unknown
- 2004-02-18 EP EP04712041A patent/EP1596862B1/en not_active Revoked
- 2004-02-18 UY UY28193A patent/UY28193A1/es not_active Application Discontinuation
- 2004-02-18 CN CNA2004800045134A patent/CN1750822A/zh active Pending
- 2004-02-18 DE DE602004030424T patent/DE602004030424D1/de not_active Expired - Lifetime
- 2004-02-18 ES ES04712041T patent/ES2357769T3/es not_active Expired - Lifetime
- 2004-02-18 MX MXPA05008757A patent/MXPA05008757A/es active IP Right Grant
- 2004-02-18 NZ NZ541862A patent/NZ541862A/en not_active IP Right Cessation
- 2004-02-18 KR KR1020057014589A patent/KR101113087B1/ko active IP Right Review Request
- 2004-02-18 AU AU2004212704A patent/AU2004212704B2/en not_active Expired
- 2004-02-18 JP JP2006501881A patent/JP2006517944A/ja active Pending
- 2004-02-18 CA CA002515946A patent/CA2515946C/en not_active Expired - Fee Related
- 2004-02-18 DK DK04712041.5T patent/DK1596862T3/da active
- 2004-02-18 PL PL378122A patent/PL378122A1/pl not_active Application Discontinuation
- 2004-02-18 EA EA200501318A patent/EA013836B1/ru not_active IP Right Cessation
- 2004-02-18 UA UAA200508834A patent/UA96254C2/uk unknown
- 2004-02-18 PT PT04712041T patent/PT1596862E/pt unknown
- 2004-02-18 BR BRPI0407549-8A patent/BRPI0407549A/pt not_active Application Discontinuation
- 2004-02-18 AT AT04712041T patent/ATE490774T1/de active
- 2004-02-18 EP EP10177400A patent/EP2258367A3/en not_active Withdrawn
- 2004-02-18 SI SI200431601T patent/SI1596862T1/sl unknown
-
2005
- 2005-08-10 US US11/201,035 patent/US20060074101A1/en not_active Abandoned
- 2005-08-11 HR HR20050709A patent/HRP20050709A2/xx not_active Application Discontinuation
- 2005-08-15 IS IS7983A patent/IS7983A/is unknown
- 2005-08-17 CU CU20050158A patent/CU23587B7/es active IP Right Grant
- 2005-08-17 ZA ZA200506580A patent/ZA200506580B/en unknown
- 2005-08-18 EC EC2005005970A patent/ECSP055970A/es unknown
- 2005-09-16 NO NO20054296A patent/NO20054296L/no unknown
- 2005-12-07 HK HK05111169.7A patent/HK1076402A1/xx not_active IP Right Cessation
-
2011
- 2011-03-04 CY CY20111100257T patent/CY1111312T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200506580B (en) | Use of palonsetron treating post-operative nausea and vomiting | |
| Ho et al. | Dexamethasone prevents postoperative nausea and vomiting: benefit versus risk | |
| US20090176698A1 (en) | Benzimidazolone Derivatives for the Treatment of Urinary Incontinence | |
| BR112019020691A2 (pt) | Composição farmacêutica contendo agonista do mor e agonista do kor, e usos da mesma | |
| US11547700B2 (en) | Compositions and methods for treating synucleinopathies | |
| US20120101089A1 (en) | Anti-Emetic Substance | |
| Robb et al. | Glycopyrrolate for treatment of clozapine-induced sialorrhea in three adolescents | |
| UA112726C2 (uk) | Нові терапевтичні комбінації міртазапіну для застосування при больових розладах | |
| Ibrahim et al. | Antiemetic medications: Agents, current research, and future directions | |
| US20230263770A1 (en) | Therapy of post-operative nausea and vomiting | |
| AU2017354899A1 (en) | Therapy of post-operative emesis with amisulpride | |
| CN1290503C (zh) | 复方樟柳碱口服液、制备方法及其用途 | |
| Meyer et al. | Pharmacology of histamine, muscarine and dopamine antagonists | |
| Ferreira et al. | Etomidate induction in an adult patient carrier of a CYP 2C9 polymorphism-Case report: 9AP3-7 | |
| NZ792875A (en) | Therapy of post-operative emesis with amisulpride | |
| Lim et al. | Efficacy of the oral neurokinin-1 receptor antagonist aprepitant administered with ondansetron for the prevention of postoperative nausea and vomiting: 9AP3-6 | |
| Marachkou et al. | Rocuronium dosing schemes applicable to obese patients: 9AP3-5 | |
| Jothi Anand | Comparison of Granisetron with the combination of Granisetron and Dexamethasone in the Prophylaxis of Post Operative Nausea and Vomiting | |
| EA044539B1 (ru) | Терапия постоперационной рвоты амисульпридом | |
| JPH10152439A (ja) | フマル酸ケトチフェン含有医薬組成物 | |
| Del Signore et al. | Therapeutics: Pharmacology, Chemotherapy, Radiation Oncology | |
| Fujii | Current prevention and treatment of postoperative nausea and vomiting after gynecological laparoscopic surgery |